NPS Pharm has $74 mil. for self-sponsored projects: Amgen has first small molecule -- Norcalcin for HPT.
Executive Summary
NPS $51.8 MIL. OFFERING CAPITALIZES ON AMGEN NORCALCIN LICENSE and the forecast of formal reports on data from four Phase I and Phase I/II studies on the calcium receptor agonist by the end of the year. The offering of 3.45 mil. shares (at $15 per share) raised approximately $48.4 mil. for the Salt Lake City-based company, increasing its cash reserves to over $74 mil. from $8.3 mil. at the end of 1995.